About Us

IPSUM applies the depth of our service offerings along with extensive therapeutic and analytical expertise to help our clients navigate the increasingly complex healthcare environment.

Our Founders

Michael Hoey

Co-Founder & CEO

Michael got his start working for Accenture in their pharmaceutical practice in the 90’s. With a focus on regulatory publishing, Michael later went to work as the CTO for a submission publishing startup called ESPS. Five years later, ESPS had a dominant market share in pharmaceutical publishing and exited with a successful IPO.

Michael Schrago

Co-Founder & Clin Ops

Michael is a pharmacologist trained and dedicated to drug discovery and development. His main areas of interest and experience are internal medicine, oncology and tropical diseases. He also has experience in biotechnology, ICH-GCP, general topics in clinical research and evidence-based medicine.

Michael Puscar

Co-Founder

Michael is an entrepreneur, investor and philanthropist who built his career in assisting early-stage companies to develop innovative products and bring them quickly to market. A product of the 1990’s technology startup boom, Michael has been bootstrapping and investing in young businesses for more than 20 years.

Our Vision

Building Capacity And Empowering For Clinical Research

With a focus on capacity building and empowering, we assist health care firms in the development of their products, by formulating, setting-up and managing clinical trials, in ways that ensure customers satisfaction, to in the last term, facilitate the access of innovative products to the market.

IPSUM applies the depth of our service offerings along with extensive therapeutic and analytical expertise to help our clients navigate the increasingly complex healthcare environment.

We work with biopharmaceutical companies with services and solutions that increase their probability of  success, connecting insights with greater delivery for improved results.

Product Development Pipeline

Our Product Development team enables pharmaceutical companies, government and non-government organizations to outsource clinical development to Colombia, from phase II to phase IV studies. Our services deliver the capabilities and knowledge as well as the analytical expertise essential to go foreword at each stage of drug development. Clinical services involve clinical monitoring and project management functions for conducting multi-site clinical trials (Phases II-IV). Strategic  planning, biostatistics and data management teams, enable IPSUM to provide innovative solutions to pharmaceutical companies wanting to conduct trials in South America.

Our consulting services provide local expertise to master the complexity of regulatory and compliance requirements. Supporting health care development is a mean that has as an ultimate purpose, to bring good to the people in the world, and this constitutes the source of inspiration and the main reason why we are always looking for ways to make contributions that make a difference.

Our Values

Client Focus

We build durable, collaborative partnerships with our clients. It begins with a profound understanding of the challenges they face. We stay flexible and always look for proactive, responsible solutions to ensure client satisfaction. Working in close partnership, we ensure their goals become reality.

Teamwork

The more minds that come together, the better the outcomes. We work together across continents, cooperating actively and mutually supporting one another to solve big challenges and meet our objectives.

Integrity

Drug development comes with a crucial responsibility of doing what’s right for patients, clients and employees. We act with an unwavering adherence to professional standards of excellence and safety.

Innovation

We cultivate an entrepreneurial spirit and are continuously looking for new ways to improve the way drugs are brought to the market.

Initiative

We encourage ingenuity, reliability and leadership from each of our employees. We acknowledge and reward excellence in performance.